Rockwell Medical, Inc. operates as an integrated biopharmaceutical company targeting end-stage renal and chronic kidney diseases in the United States and internationally. The company's lead drug includes Triferic, an iron maintenance therapy that replaces the iron lost by patients during hemodialysis treatment. It also provides Calcitriol, a generic active vitamin D injection, which is indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, the company manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. Its concentrated dialysate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. Rockwell Medical, Inc. sells its products directly, as well as through independent sales agents and distributors. The company's target customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and technical and purchasing personnel. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.
Industry, Sector and Symbol
Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
Phone248-960-9009
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$57.30 million
Profitability
Miscellaneous
Employees300
OptionableOptionable
Rockwell Medical (NASDAQ:RMTI) Frequently Asked Questions
What is Rockwell Medical's stock symbol?
Rockwell Medical trades on the NASDAQ under the ticker symbol "RMTI."
How were Rockwell Medical's earnings last quarter?
Rockwell Medical Inc (NASDAQ:RMTI) announced its earnings results on Friday, November, 9th. The company reported ($0.10) EPS for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.05. The business earned $16.67 million during the quarter, compared to the consensus estimate of $15 million. Rockwell Medical had a negative net margin of 53.40% and a negative return on equity of 117.31%. View Rockwell Medical's Earnings History.
When is Rockwell Medical's next earnings date?
What price target have analysts set for RMTI?
1 equities research analysts have issued 1-year target prices for Rockwell Medical's stock. Their predictions range from $11.00 to $11.00. On average, they anticipate Rockwell Medical's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 251.4% from the stock's current price. View Analyst Price Targets for Rockwell Medical.
What is the consensus analysts' recommendation for Rockwell Medical?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rockwell Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Rockwell Medical.
Has Rockwell Medical been receiving favorable news coverage?
Media coverage about RMTI stock has trended very positive this week, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Rockwell Medical earned a news impact score of 3.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are some of Rockwell Medical's key competitors?
Some companies that are related to Rockwell Medical include Viewray (VRAY), AxoGen (AXGN), Semler Scientific (SMLR), BioLife Solutions (BLFS), Cutera (CUTR), Electrocore (ECOR), Fonar (FONR), Zynex (ZYXI), Edap Tms (EDAP), Biosig Technologies (BSGM), Stereotaxis (STXS), IRIDEX (IRIX), Second Sight Medical Products (EYES), Viveve Medical (VIVE) and Soleno Therapeutics (SLNO).
Who are Rockwell Medical's key executives?
Rockwell Medical's management team includes the folowing people:
- Dr. Ajay Gupta, Chief Scientific Officer & Member of Scientific Advisory Board (Age 61)
- Dr. Raymond Dennis Pratt, Chief Medical Officer (Age 68)
- Mr. Stuart Paul, Pres, CEO & Director
- Mr. Angus W. Smith, Chief Financial Officer (Age 36)
- Mr. Michael DeYoung, VP of Operations
How do I buy shares of Rockwell Medical?
Shares of RMTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Rockwell Medical's stock price today?
One share of RMTI stock can currently be purchased for approximately $3.13.
How big of a company is Rockwell Medical?
Rockwell Medical has a market capitalization of $178.34 million and generates $57.30 million in revenue each year. The company earns $-25,920,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis. Rockwell Medical employs 300 workers across the globe.
What is Rockwell Medical's official website?
How can I contact Rockwell Medical?
Rockwell Medical's mailing address is 30142 S WIXOM RD, WIXOM MI, 48393. The company can be reached via phone at 248-960-9009 or via email at [email protected]
MarketBeat Community Rating for Rockwell Medical (NASDAQ RMTI)
MarketBeat's community ratings are surveys of what our community members think about Rockwell Medical and other stocks. Vote "Outperform" if you believe RMTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
